CGTX

Company Overview — What Does COGNITION THERAPEUTICS INC Do?

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York. COGNITION THERAPEUTICS INC (CGTX) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Lisa R. Ricciardi and employs approximately 20 people. With a market capitalization of $80M, CGTX is one of the notable companies in the Healthcare sector.

COGNITION THERAPEUTICS INC (CGTX) Stock Rating — Avoid (April 2026)

As of April 2026, COGNITION THERAPEUTICS INC receives a Avoid rating with a composite score of 25.8/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.CGTX ranks #4,159 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, COGNITION THERAPEUTICS INC ranks #733 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

CGTX Stock Price and 52-Week Range

COGNITION THERAPEUTICS INC (CGTX) currently trades at $0.91. The stock gained $0.05 (5.4%) in the most recent trading session. The 52-week high for CGTX is $3.83, which means the stock is currently trading -76.3% from its annual peak. The 52-week low is $0.22, putting the stock 308.0% above its annual trough. Recent trading volume was 555K shares, suggesting relatively thin trading activity.

Is CGTX Overvalued or Undervalued? — Valuation Analysis

COGNITION THERAPEUTICS INC (CGTX) carries a value factor score of 14/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 2.13x, versus the sector average of 2.75x.

At current multiples, COGNITION THERAPEUTICS INC trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

COGNITION THERAPEUTICS INC Profitability — ROE, Margins, and Quality Score

COGNITION THERAPEUTICS INC (CGTX) earns a quality factor score of 15/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -87.8%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -62.2% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

CGTX Debt, Balance Sheet, and Financial Health

COGNITION THERAPEUTICS INC has a debt-to-equity ratio of 41.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 3.45x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $39M.

CGTX has a beta of 1.95, meaning it is more volatile than the broader market — a $10,000 investment in CGTX would be expected to move 94.7% more than the S&P 500 on any given day. The stability factor score for COGNITION THERAPEUTICS INC is 11/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

COGNITION THERAPEUTICS INC Revenue and Earnings History — Quarterly Trend

In TTM 2026, COGNITION THERAPEUTICS INC reported revenue of $0 and earnings per share (EPS) of $-0.32. Net income for the quarter was $-30M. Operating income came in at $-49M.

In FY 2025, COGNITION THERAPEUTICS INC reported revenue of $0 and earnings per share (EPS) of $-0.32. Net income for the quarter was $-23M. Operating income came in at $-48M.

In Q3 2025, COGNITION THERAPEUTICS INC reported revenue of $0 and earnings per share (EPS) of $-0.06. Net income for the quarter was $-5M. Operating income came in at $-6M.

In Q2 2025, COGNITION THERAPEUTICS INC reported revenue of $0 and earnings per share (EPS) of $-0.11. Net income for the quarter was $-7M. Operating income came in at $-14M.

Over the past 8 quarters, COGNITION THERAPEUTICS INC has experienced revenue contraction from $0 to $0. Investors analyzing CGTX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

CGTX Dividend Yield and Income Analysis

COGNITION THERAPEUTICS INC (CGTX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

CGTX Momentum and Technical Analysis Profile

COGNITION THERAPEUTICS INC (CGTX) has a momentum factor score of 46/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 41/100 reflects moderate short selling activity.

CGTX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, COGNITION THERAPEUTICS INC (CGTX) ranks #733 out of 838 stocks based on the Blank Capital composite score. This places CGTX in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing CGTX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CGTX vs S&P 500 (SPY) comparison to assess how COGNITION THERAPEUTICS INC stacks up against the broader market across all factor dimensions.

CGTX Next Earnings Date

No upcoming earnings date has been announced for COGNITION THERAPEUTICS INC (CGTX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy CGTX? — Investment Thesis Summary

The quantitative profile for COGNITION THERAPEUTICS INC suggests caution. The quality score of 15/100 flags below-average profitability. The value score of 14/100 indicates premium valuation. High volatility (stability score 11/100) increases portfolio risk.

In summary, COGNITION THERAPEUTICS INC (CGTX) earns a Avoid rating with a composite score of 25.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CGTX stock.

Related Resources for CGTX Investors

Explore more research and tools: CGTX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CGTX head-to-head with peers: CGTX vs AZN, CGTX vs SLGL, CGTX vs VMD.